Ji Woo Yeon

Jan 23, 2025 | dailypharmkorea.com | Ji Woo Yeon

Dr. Yang Won Lee, Professor in the Department of Dermatology at Konkuk University Medical Center Emphasizes the importance of a patient-customized strategy, as various treatment options for atopic dermatitis are available A biological agent, Ebglyss, emerges as a new treatment option…fewer conjunctivitis side effects Points out the limited treatment options based on a patient's condition…mentions the necessity for drug switching, regardless of drug-type Atopic dermatitis treatment settings...

Jan 20, 2025 | dailypharmkorea.com | Ji Woo Yeon

Dr. Hong Koo Ha, Professor in the Department of Urology at Pusan National University Hospital Benefits observed in patients prescribed Extandi align with those in the ARCHES Phase 3 study Emphasizes the role of regional hospitals in treating prostate cancer, prevalent in older age As more treatment options are covered by reimbursement, concerns about 'how' best to treat prostate cancer are increasing. Given the increasing number of prostate cancer patients increases each year, it is important...

Jan 12, 2025 | dailypharmkorea.com | Ji Woo Yeon

Have signed 14 out-licensing deals this year… major achievements by Orum Therapeutics‧Alteogen Demonstrated performance in global pharma developments, focusing on trends in ADC‧autoimmune disease areas Korean pharmaceutical and biotech companies have successfully outlicensed new drugs in various fields, including cancer, autoimmune disease, and Alzheimer's disease. However, compared to the year before, analysis suggests that the number of out-licensed cases decreased. Despite such a slowdown,...

Jan 8, 2025 | dailypharmkorea.com | Ji Woo Yeon

Novo Nordisk enters the market early as part of winning strategy…Lilly responds with clinical superiority In addition to the sleep apnea indication, the MASH indication is being considered… the key is company's exploring price and formation diversification As more people are living with obesity in the world, obesity treatment is gaining popularity.

Jan 8, 2025 | dailypharmkorea.com | Ji Woo Yeon

HIRA disclosed reports from the DREC review held in November last year Priced higher than that of alternative drugs…does not meet the criteria for an economic assessment ▲ Product photo of Mylotarg The high price was found to be the reason Pfizer Korea's new drug Mylotarg (gemtuzumab ozogamicin), a treatment for acute myeloid leukemia (AML), did not pass the Health Insurance Review and Assessment Service (HIRA) stage. HIRA acknowledged the drug's improvement in clinical utility but did not...